{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-144274","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.020378+00:00","generated_at":"2026-06-15T01:33:48.627462+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ikena raises ~$40M in equity offering; Q1 cash $137.8M; runway to 2026","bullets":["Underwritten offering of 6.11M shares at $6.55/share for gross proceeds of ~$40M; closing expected May 17, 2023.","Cash, equivalents and marketable securities $137.8M at March 31, 2023; offering proceeds extend cash runway into 2026.","Q1 collaboration revenue $5.3M (up from $3.4M YoY); R&D expense $15.6M; G&A $5.3M.","IK-930 initial monotherapy data expected 4Q 2023; IK-595 IND filing planned 2H 2023; IK-175 Fast Track designation in March."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-144274","json":"https://secwatch.observer/filing/0001193125-23-144274.json","markdown":"https://secwatch.observer/filing/0001193125-23-144274.md","text":"https://secwatch.observer/filing/0001193125-23-144274.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523144274/0001193125-23-144274-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523144274/d504516d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:33:48.627462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c9e31cd4ed272a06e7ed4feead8073c9b1a1176","claim":"ImageneBio, Inc. entered into Underwriting Agreement with Cowen and Company, LLC and William Blair & Company, L.L.C., as representatives of the underwriters valued at approximately $40,020,500 million (effective 2023-05-15).","evidence_excerpt":"On May 15, 2023, Ikena Oncology, Inc., a Delaware corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and William Blair & Company, L.L.C., as representatives of the underwriters listed on Schedule A thereto (collectively, the “Underwriters”), relating to an underwritten registered offering (the “Offering”) of 6,110,000 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at a price of $6.550 per share, less underwriting discounts and commissions.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523144274/0001193125-23-144274-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Cowen and Company, LLC and William Blair & Company, L.L.C., as representatives of the underwriters"},{"label":"Value","value":"approximately $40,020,500 million"},{"label":"Effective","value":"2023-05-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}